retatrutide clinical trials latest Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial On The Pen™ * @ManOnThePen•4h

Yamamoto, W., Sugiura, A., Nakazato-Imasato, E

Thousands of lawsuits have been filed by Ozempic patients who have experienced a range of complications, including blindness

Monitor closely Track your body weight, changes in blood sugar levels, appetite changes, and side effects carefully, and consult with your doctors if you have any questions

The safety and efficacy of citrus aurantium (bitter orange) extracts and p-synephrine: a systematic review and meta-analysis

TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes